The Latest Breaking News from Testosterone

Sebastian Coe suggested his sport may follow swimming’s lead, saying ‘biology trumps gender’ and World Athletics’ policies will reflect this

Petr Holy, a urological specialist at Men's Health Clinic Kingston, has shared some of the common signs of low testosterone.

Transgender cyclist Emily Bridges, who hit the headlines in March after it emerged she was set to compete in the National Omnium Championships only to be blocked, revealed the negative response to Boris Johnson's recent comments

The dual Olympic champion speaks about the impact of taking hormonal medication, as well as being subjected to invasive "gender verification" testing by World Athletics.

MONTEREY, California — Seventeen Mile Drive along the California coast is paved with testosterone.

Erectile Dysfunction can become an increasing problem as men get older. While this issue is a normal part of the ageing process, new research shows that it is also a key predictor of early mortality.

Lipocine Inc (NASDAQ:LPCN) has announced topline results from its Open-Label Extension (OLE) study of LPCN 1144, including an orally delivered prodrug of testosterone. Twenty-five subjects were enrolled, of whom 16 subjects from the LiFT study continued LPCN 1144 treatment for additional 36 weeks (total of 72 weeks), and nine subjects initiated LPCN 1144…

Promotions for “The End of Men,” Fox News host Tucker Carlson’s forthcoming documentary, lament “The total collapse of testosterone levels in American men.”

NEW DELHI: India’s leading discus thrower and Tokyo Olympian, Kamalpreet Kaur, has been provisionally suspended for failing the dope test for an anabolic steroid, TOI can confirm. Kamalpreet, the first Indian woman to breach the 65m barrier in discus throw, has been put under provisional suspension since April 1. The…

Testosterone in men does indeed have profound effects on mood, being demonstrated to improve depression, happiness and motivation.

The European Commission (EC) has approved Myovant Sciences Ltd's (NYSE:MYOV) Orgovyx (relugolix, 120 mg) for advanced hormone-sensitive prostate cancer.  This approval was supported by data from the Phase 3 HERO study. In the HERO study, Orgovyx met the primary endpoint and achieved sustained testosterone suppression to castrate levels (< 50 ng/dL) through 48…